Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19.

Autor: Cheng-Pu Sun, Jia-Tsrong Jan, I-Hsuan Wang, Hsiu-Hua Ma, Hui-Ying Ko, Ping-Yi Wu, Tzu-Jiun Kuo, Hsin-Ni Liao, Yu-Hua Lan, Zong-Lin Sie, Yen-Hui Chen, Yi-An Ko, Chun-Che Liao, Liang-Yu Chen, I-Jung Lee, Szu-I Tsung, Yun-Ju Lai, Ming-Tsai Chiang, Jian-Jong Liang, Wen-Chun Liu, Jing-Rong Wang, Joyce Pei-Yi Yuan, Yin-Shiou Lin, Yi-Ching Tsai, Shie-Liang Hsieh, Chia-Wei Li, Han-Chung Wu, Tai-Ming Ko, Yi-Ling Lin, Mi-Hua Tao
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: PLoS Pathogens, Vol 17, Iss 8, p e1009758 (2021)
Druh dokumentu: article
ISSN: 1553-7366
1553-7374
DOI: 10.1371/journal.ppat.1009758
Popis: Since the pandemic of COVID-19 has intensely struck human society, small animal model for this infectious disease is in urgent need for basic and pharmaceutical research. Although several COVID-19 animal models have been identified, many of them show either minimal or inadequate pathophysiology after SARS-CoV-2 challenge. Here, we describe a new and versatile strategy to rapidly establish a mouse model for emerging infectious diseases in one month by multi-route, multi-serotype transduction with recombinant adeno-associated virus (AAV) vectors expressing viral receptor. In this study, the proposed approach enables profound and enduring systemic expression of SARS-CoV-2-receptor hACE2 in wild-type mice and renders them vulnerable to SARS-CoV-2 infection. Upon virus challenge, generated AAV/hACE2 mice showed pathophysiology closely mimicking the patients with severe COVID-19. The efficacy of a novel therapeutic antibody cocktail RBD-chAbs for COVID-19 was tested and confirmed by using this AAV/hACE2 mouse model, further demonstrating its successful application in drug development.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje